OTCMKTS:RCDTF Recordati Industria Chimica E Farmaceutica (RCDTF) Stock Price, News & Analysis $58.00 0.00 (0.00%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsShort Interest About Recordati Industria Chimica E Farmaceutica Stock (OTCMKTS:RCDTF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RCDTF alerts:Sign Up Key Stats Today's Range$58.00▼$58.0050-Day Range$58.00▼$58.0052-Week Range$55.88▼$60.00Volume7 shsAverage Volume1 shsMarket Capitalization$11.97 billionP/E Ratio20.68Dividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Recordati Industria Chimica e Farmaceutica S.p.A. is an Italy-based pharmaceutical company focused on the research, development, manufacture and commercialization of prescription medicines. Its business is centered on specialty-care and rare-disease treatments, as well as selected products for primary care and other therapeutic areas. The company’s portfolio includes medicines for conditions such as endocrine disorders, cardiovascular disease, central nervous system disorders and rare diseases. Recordati markets both proprietary products and established branded medicines, including treatments based on active ingredients such as osilodrostat, cariprazine and lercanidipine. Its rare-disease operations expanded through the acquisition of EUSA Pharma, which added products for specialized and orphan indications. Founded in Italy in 1926 by Giovanni Recordati, the company has developed from a domestic pharmaceutical business into an international group. Recordati serves healthcare markets across Europe and in other regions, including the United States and selected countries in the Middle East, North Africa and Latin America. The group is headquartered in Milan, Italy, and is led by Chief Executive Officer Rob Koremans, with Andrea Recordati serving as chairman.AI Generated. May Contain Errors. Read More Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica E Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCDTF Stock News HeadlinesHead-To-Head Survey: Shineco (NASDAQ:SISI) versus Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)September 17, 2026 | americanbankingnews.comIl piccolo azionista deve sapere queste cose prima dell'OPA di Recordati del 31 agostoAugust 26, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Recordati, il cda approva l’opas: “Nessun rilancio, prezzo congruo”. Ma gli indipendenti dicono noJuly 16, 2026 | msn.comRecordati, il cda si spacca sull'opa. Gli indipendenti bocciano il prezzo, via libera con sei voti su dieciJuly 16, 2026 | msn.comCVC, GBL launch €10.7 billion bid for Italian drugmaker RecordatiMay 22, 2026 | reuters.comRecordati SpA (RCDTF) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and R&D ...May 15, 2026 | uk.finance.yahoo.comRECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%May 12, 2026 | markets.businessinsider.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica E Farmaceutica's stock was trading at $65.44 on January 1st, 2026. Since then, RCDTF shares have decreased by 11.4% and is now trading at $58.00. How were Recordati Industria Chimica E Farmaceutica's earnings last quarter? Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) issued its earnings results on Wednesday, July, 29th. The company reported $0.91 earnings per share for the quarter. The business earned $810.70 million during the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 18.38% and a trailing twelve-month return on equity of 33.73%. How do I buy shares of Recordati Industria Chimica E Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2026Today9/24/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,693Year Founded1926Profitability EPS (Trailing Twelve Months)$2.80 Trailing P/E Ratio20.68 Forward P/E RatioN/A P/E GrowthN/ANet Income$501.92 million Net Margins18.38% Pretax Margin22.20% Return on Equity33.73% Return on Assets12.76% Debt Debt-to-Equity Ratio0.79 Current Ratio1.26 Quick Ratio0.86 Sales & Book Value Annual Sales$2.96 billion Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares206,300,000Free FloatN/AMarket Cap$11.97 billion OptionableNot Optionable Beta0.25 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica E Farmaceutica S.P.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica E Farmaceutica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCDTF Stock Alerts